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Abstract. Purpose: Radio-iododeoxyuridine (IdUrd) is a
potential Auger radiation therapy agent incorporated into
DNA during the synthesis phase. In this study we sought
to optimise S-phase targeting by modulating cellular
cycling and radio-IdUrd DNA incorporation using short
non-toxic fluorodeoxyuridine (FdUrd) incubations.
Methods: Three human glioblastoma cell lines with
different p53 expression were pre-treated with various
FdUrd conditions. After different intervals, 125I-IdUrd
DNA incorporation was measured. Fluorescence-activated
cell sorter cell cycle analysis was performed after identical
intervals post FdUrd pre-treatment.
Results: The highest increase in 125I-IdUrd DNA incor-
poration was induced by 1-h incubation with 1 μM FdUrd.
Increase in radio-IdUrd DNA incorporation was greatest
16–24 h after FdUrd, reaching factors of ≥7.5 over
baseline incorporation in the three cell lines. Furthermore,
cell synchronisation in S phase was observed with a peak
of ≥69.5% in the three cell lines at 16 and 24 h post
FdUrd, corresponding to an increase of 2.5–4.1 over
baseline.
Conclusion: FdUrd-induced thymidine synthesis inhibi-
tion led to S-phase accumulation that was maximal after an
interval of 16–24 h and time-correlated with the highest
radio-IdUrd DNA incorporation. These observations
might allow the rational design of an Auger radiation
therapy targeting a maximal number of S-phase cells in
single treatment cycles.
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Introduction
Iododeoxyuridine (IdUrd), a thymidine (dThd) analogue,
labelled with 123I or 125I, is an interesting Auger radiation
therapy agent [1]. However, two major limitations restrict
its DNA incorporation and therapeutic efficacy: firstly,
radio-IdUrd DNA incorporation is low because of compe-
tition from the endogenous nucleotide pool and a short
biological half-life attributable to rapid in vivo catabolism
and dehalogenation [2, 3], and secondly, therapeutic IdUrd
targeting is restricted to cells in the synthesis phase (S
phase) of the cell cycle. Thus, for the short period of its in
vivo availability, only cells in S phase can be efficiently
targeted with radio-IdUrd.
In order to favour DNA incorporation of IdUrd,
different groups, including ours, have studied inhibition
of the de novo synthesis of dThd with agents such as
fluorodeoxyuridine (FdUrd) [4–6], 5-fluorouracil [7] or
methotrexate [7]. FdUrd, a dThd analogue, inhibits
thymidylate synthase (TS) and depletes the TTP pool by
acting as non-convertible substrate [8]. The depletion of the
cellular TTP pool favours incorporation into DNA of
exogenous dThd and dThd analogues such as IdUrd [4–7].
FdUrd has been shown to have an extended effect on TS
inhibition even after its removal in the human colon
carcinoma cell line HT 29 [9]. Clinically, push adminis-
tration of FdUrd, used in the early 1960s, is also well
tolerated at high doses [10]. However, prolonged exposure
to low doses of FdUrd leads to clonogenic death of HT29
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cells [11]. Our recent studies [6, 12] have shown that short
i.v. treatment of animals with FdUrd allows a significant
improvement in tumour DNA incorporation of radio-
IdUrd. However, while different groups have shown that
FdUrd pre- or co-treatment results in the expected increase
in incorporation of radio-IdUrd into DNA [4–7], a
corresponding improvement in the efficacy of treatment
has not been observed [4].
Due to the absence of improved efficacy of the different
Auger radiation therapy approaches with radio-IdUrd (also
evident in personal unpublished observations), we ad-
vanced the hypothesis that the limitation of S-phase
targeting has not been addressed adequately. In fact, our
previous observation of increased radio-IdUrd DNA
incorporation immediately post FdUrd treatment [6, 12]
still targeted only the very limited number of cells in S
phase at radio-IdUrd incubation in vitro or injection in
vivo. Therefore, in this study we investigated whether
S-phase accumulation might be achieved in different glio-
blastoma cell lines. If S-phase accumulation and simulta-
neous high efficacy of radio-IdUrd DNA incorporation
could be obtained, we would expect these combined effects
to allow the design of a more rational Auger radiation
therapy approach.
Materials and methods
Reagents
125I-IdUrd of high radiochemical purity was prepared from the
precursor 5-tri-n-butyl-stannyl-2'-deoxyuridine and purified by
SepPak RP-18 cartridges using a modified method [13] described
originally by Foulon et al. [14]. Radiochemical purity was repeatedly
verified with thin-layer chromatography using polyethyleneimine
cellulose F strips (Merck, Darmstadt, Germany) with a mobile phase
of 0.2 M ammonium bicarbonate and radioactivity reading on a
Tracemaster 20 (Berthold, Bad Wildbad, Germany). In all experi-
ments, 125I-IdUrd represented >98% of overall 125I activity. In the
production of 125I-IdUrd, we were able to avoid contamination with
unlabelled IdUrd [13]. It was calculated that the standard activity of
5 kBq 125I-IdUrd in 0.5 ml used in the incorporation experiments
represented a concentration of 0.2 nM, though this is only an
indicative value as it has not been experimentally verified. FdUrd and
dThd were obtained from Sigma-Aldrich Chemie GmbH (Steinheim,
Germany). Stock solutions were prepared in distilled water at a
concentration of 5 mM and stored at −80°C. Unlabelled IdUrd
(Sigma-Aldrich Chemie GmbH) was dissolved in physiological
NaCl using NaOH at minimally required concentration and stock
solution (50 mM) stored at −80°C
Cell lines and culture
Three human glioblastoma cell lines were chosen for their different
p53 expression [15] that could potentially provide them with
different repair capacities or FdUrd resistance [16]: U251 and U87
(American Type Culture Collection, ATCC) homozygous mutant and
homozygous wild type, respectively, and the heterozygous line
LN229 (gift from Prof. N. de Tribolet, Service of Neurosurgery,
University Hospital, Geneva, Switzerland). Cells were cultured at
37°C and 5% CO2 in RPMI 1640 with glutamax I, supplemented
with 10% heat-inactivated fetal bovine serum (Chemie Brunschwig
AG, Basel, Switzerland), penicillin (50 units/ml) and streptomycin
(0.05 mg/ml; Life Technologies Inc., Grand Island, NY, USA), which
was changed twice a week. Cell doubling times in culture flasks as
measured by daily counting over 1 week were 24.6±2.3 h, 33.7±3.4 h
and 34.0±0.2 h for U251, LN229 and U87, respectively (n≥3).
Because mycoplasma contamination is a potential source of in-
creased nucleoside turnover [17, 18] and could therefore modulate
FdUrd efficacy, all cells were tested negative for four major poten-
tial mycoplasma contaminations (Mycoplasma Detection Kit, F.
Hoffmann-La Roche Ltd, Basel, Switzerland), and maximal cell
culture time after testing was 6 months.
125I-IdUrd incorporation assay
To assess the effect of FdUrd on 125I-IdUrd incorporation into DNA,
24-well culture dishes were plated with 20,000 cells for LN229 and
U87, and with 15,000 cells for U251. After 4 days, the exponentially
growing cells were pre-treated for varying times and with varying
doses of FdUrd, and washed twice with PBS (NaCl 0.15 M,
phosphate 0.01 M, pH 7.4) before fresh medium was added. After
different intervals of 0–72 h, cells were incubated for 2 h at 37°C
with 5 kBq 125I-IdUrd in 0.5 ml medium. In a time course experiment
with LN229 and U251 cells, we had observed that after incubation of
cells for 2 h, the large majority of intracellular radio-IdUrd was
incorporated into DNA (results not shown). In accordance with
published protocol [4, 19], cells were washed once with complete
medium, twice with PBS and then recovered in 5-ml plastic tubes
after incubation for 10 min with 200 μl of trypsin-EDTA (Life
Technologies Inc.). Wells were washed with 200 μl complete
medium and this wash was also added to the cells. Thereafter, cells
were lysed with 400 μl of 1 M NaOH. The DNA was precipitated
with the addition of 400 μl of 10% trichloroacetic acid (Sigma-
Aldrich Chemie GmbH) and the total volume of 1.2 ml centrifuged
for 30 min at 3,500 g. A half volume was separated as one-half
supernatant, and the remaining half volume (0.6 ml) was considered
as sediment (containing DNA) plus another half supernatant.
Radioactivity was determined in a gamma counter (Wizard 3”
1480 automatic gamma counter, Wallac Oy, Turku, Finland) and
results expressed for total cellular uptake (sediment + supernatant) of
radio-IdUrd and for DNA-incorporated activity (sediment alone). All
results given here represent DNA-incorporated radioactivity that was
generally >85% of cell-bound activity. In all timing experiments,
cells were counted in identically treated control wells and DNA-
incorporated activity was normalised according to the number of
cells.
Fluorescence-activated cell sorter (FACS) analysis
Cells were analysed by two-parameter flow cytometry measuring
both DNA content by propidium iodide (PI) (Fluka Chemie AG,
Buchs, Switzerland) and labelling index with IdUrd [6]. Exponen-
tially growing cells were either pre-treated or not with 1 μM FdUrd
for 1 h, washed with PBS, incubated in fresh medium for 0–72 h and
labelled with 10 μM non-radioactive IdUrd for 1 h. For LN229 and
U251 cells, one of three experiments was performed with 3 μM
IdUrd. Cells were then washed twice with PBS, trypsinised,
centrifuged for 15 min at 500 g, resuspended in PBS, diluted and
fixed as aliquots of 106 cells in 4 ml 70% cold ethanol for 30 min on
ice. Cells were centrifuged for 10 min at 500 g and 4°C. The DNA
was denatured by incubating the cells in 1 ml 2 M HCl/0.5% BSA/
PBS for 30 min at room temperature. Cells were centrifuged, and
acid cell sediment was neutralised by resuspension in 1 ml of 0.1 M
sodium borate at pH 8.5. After centrifugation for 10 min at 500 g,
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cells were either stored at −20°C or directly prepared for FACS
analysis by incubating them for 30 min at room temperature in 50 μl
0.5% Tween 20/0.5% BSA/PBS containing 0.5 μg of mouse
monoclonal antibody against anti-BrdUrd (Dako A/S, Glostrup,
Denmark) cross-reacting with IdUrd. After incubation, 1 ml PBS was
added before centrifugation (10 min at 500 g and 4°C). Then, the
pellet was resuspended in 50 μl of 0.5% Tween 20/0.5% BSA/PBS
with 1 μg of anti-mouse IgG conjugated with FITC (Sigma-Aldrich
Chemie GmbH) and incubated for another 30 min at room
temperature. Cells were washed with 1 ml PBS, centrifuged and
resuspended in 1 ml of PBS containing 2.5 μg/ml PI. Samples were
incubated for 16–20 h at 4°C before analysis on a flow cytometer
(FACScan; Becton Dickinson, Franklin Lakes, NJ, USA) with a laser
excitation at 488 nm for PI and FITC fluorescence.
External beam irradiation and cell survival assay
Twenty-four well culture dishes were plated with 20,000 and 15,000
cells for LN229 and U251, respectively, 4 days prior to treatment.
After pre-treatment for 1 h with 1 μM FdUrd, cells were washed, re-
incubated with fresh medium and irradiated at the times indicated in a
photon beam (6 MeV Primus Linear Accelerator, Siemens AG,
Munich, Germany) at doses of 2 or 6 Gy. The colony-forming assay
was then used to measure the cell survival fraction: cells were
trypsinised, resuspended in RPMI 1640 and counted. The cell
suspension was serially diluted and 200 or 2,000 viable cells were
plated into 100×20 mm tissue culture dishes in 10 ml fresh culture
medium. After 14 days of incubation at 37°C and 5% CO2, grown
colonies were fixed and stained with 0.5% crystal violet in methanol/
acetic acid (3:1, v/v). Colonies containing ≥50 cells were counted.
Each experiment was performed using triplicates and repeated at
least three times. The survival fraction (S/S0) was calculated as the
plating efficiency of irradiated pre-treated cells divided by the plating
efficiency of corresponding unirradiated pre-treated cells. The
colony-forming assay cannot be performed in liquid medium with
U87 cells because they form spheroids and can detach. For this
reason, this line was not tested in this assay.
Statistical analysis
Statistical multi-group comparisons were performed with the
ANOVA multiple range Tukey-HSD test at different confidence
levels using the UNISTAT 5.5 statistical package for Windows (2002
edition, Unistat Ltd, London, UK, run on Windows XP). The Tukey-
HSD test applies the largest range value independent of the effective
subset size; it is more conservative than the Student-Newman-Keuls
test but less conservative than the Scheffé or the Bonferroni test.
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Fig. 1. Increase in DNA incorporation (I/Io) of 125I-IdUrd according
to the concentration of FdUrd. Cells were co-incubated with 5 kBq
125I-IdUrd and with/without FdUrd (0.001–100 μM). Results (mean±1
SD) are from three independent experiments, each performed with
three samples per test condition. Results are normalised to control
samples incubated for 4 h with radio-IdUrd alone. Additional
controls of incorporation were performed by competition with
50 μM thymidine (+dThd)
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Fig. 2. Incorporation kinetics of 125I-IdUrd according to the interval
after FdUrd pre-treatment, for LN229 (a), U251 (b) and U87 (c) cell
lines. The different pre-treatments were: 1 μM FdUrd for 1 h (♦),
10 μM FdUrd for 1 h (∆), 1 μM FdUrd for 10 min (■) and 10 μM
FdUrd for 10 min (○). After various intervals post FdUrd pre-
treatment, cells were incubated for 2 h with 5 kBq 125I-IdUrd. The
mean values ±1 SD of three independent experiments are shown,
each performed with three to four measurements per condition. The
results represent relative increase in DNA incorporation of radio-
IdUrd for pre-treated cells divided by untreated samples (I/Io) and
normalised to the number of cells per well. Baseline relative DNA
incorporation is represented by a broken line. * and ** denote results
that were significantly (p<0.05) or highly significantly (p<0.001)
different compared with untreated control cells
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Results
Dependence of 125I-IdUrd DNA incorporation on FdUrd
concentration
First experiments were performed on the three glioblasto-
ma cell lines in exponential growth using co-incubation for
4 h with 5 kBq 125I-IdUrd and different concentrations of
FdUrd. Depending on the FdUrd concentration, increased
DNA incorporation of radio-IdUrd up to a plateau was
observed compared with untreated cells. A maximum
increase in incorporation of 4.0- to 8.5-fold was obtained in
the three cell lines with FdUrd concentrations between 0.01
and 3 μM (Fig. 1). A high percentage incorporation of
radio-IdUrd in absolute amount (results not shown) might
have been partially responsible for the observed plateau. At
concentrations of 10 μM FdUrd or higher, the DNA
incorporation of radio-IdUrd decreased in all cells and co-
incubation with dThd almost completely abolished it
(Fig. 1). Compared with previous experiments [6], the
results presented here show a higher efficacy of FdUrd and
a higher absolute amount of radio-IdUrd incorporated. This
might be related to mycoplasma contamination in previous
experiments, though this has not been formally demon-
strated. The cells used here, however, were checked for the
absence of mycoplasma contamination.
Delayed effect of FdUrd pre-treatment on DNA
incorporation of 125I-IdUrd
Shorter incubation times of 10 and 60 min with 1 and
10 μM FdUrd were further evaluated because of the known
low toxicity and efficacy of such treatments [6, 10].
Though some growth delay was observed with direct cell
counting, absence of cytotoxicity of these treatments was
confirmed in LN229 and U251 cells with the colony-
forming assay (results not shown). Cells were pre-treated
with FdUrd, washed to eliminate trace amounts of FdUrd
that could influence the cell cycle and re-incubated with
fresh medium for 0–72 h, following which the radio-IdUrd
incorporation rate was measured in a 2-h incubation.
Incubation with 1 μM FdUrd for 1 h was the pre-treatment
which gave the highest increase in 125I-IdUrd DNA
incorporation and the most prolonged effect for the three
glioblastoma cell lines (Fig. 2). Under this condition, the
incorporation rate increased to a maximum after an interval
of 16–24 h post FdUrd pre-treatment (all results are
corrected for the number of counted cells). Incorporation
increased by factors of 7.5, 10 and 12 or more for LN229,
U87 and U251, respectively, compared with un-pretreated
cells (p>0.001). This corresponded, at 24 h post FdUrd, to
16.4%, 35.1% and 50.7% DNA incorporation in absolute
amount calculated on the total radio-IdUrd present during
the 2-h incubation for the LN229, U87 and U251,
respectively (results not shown). The immediate increase
in incorporation post FdUrd exposure (time 0, Fig. 2) was
similar to that seen in the 4-h co-incubation experiments
shown above, but it was significantly less (p<0.05 for the
three cell lines) than at 16 and 24 h post FdUrd. The other
pre-treatments also favoured 125I-IdUrd DNA incorpora-
tion, but the increase in incorporation was not as high as
with 1 μM FdUrd for 1 h. In particular, the shorter
incubation period of 10 min was insufficient to produce a
similar effect, despite the use of a higher concentration of
FdUrd. Furthermore, the maximum increase in incorpora-
tion tended to occur earlier post FdUrd for the other pre-
treatments (Fig. 2).
Cell cycle distribution according to the interval after
FdUrd pre-treatment
Cell cycle distribution was then assessed by double
staining FACS analysis after the optimal pre-treatment
for 1 h with 1 μM FdUrd. Highly reproducible results were
observed in independent experiments performed with
LN229, U251 and U87 cells. Incubation with 3 μM (one
experiment performed on LN229 and U251 cells) or 10 μM
IdUrd (two experiments on the three cell lines) gave
identical results, which were pooled (Table 1). As controls,
antibody anti-IdUrd staining was negative for cells
Table 1. Cell cycle FACS analysis
Interval 0 h 3 h 6 h 16 h 24 h 48 h 72 h Untreated controls
LN229 G1 62.9±1.4 60.3±2.1 56.1±3.0 19.5±0.4** 18.3±3.6** 43.8±8.0** 68.4±2.9 64.2±1.3
S 30.3±1.1 34.0±3.0 39.5±1.9[*] 75.7±1.3** 71.4±4.6** 47.3±7.6* 23.7±2.1 28.7±1.4
G2 5.4±0.1 3.9±0.7 1.8±0.3* 2.7±0.3* 9.0±2.2[*] 6.8±0.9 6.2±0.5 6.2±0.6
U251 G1 55.8±1.9 56.8±2.6 54.8±3.5 25.2±1.7** 18.7±1.2** 52.8±12.1 77.8±0.6(*) 60.5±3.1
S 27.9±2.4[*] 26.7±1.8 34.0±4.1* 69.5±1.8** 76.0±1.0** 26.8±7.4 6.4±0.5(*) 18.5±2.3
G2 15.7±0.5* 16.2±1.5* 10.2±1.0** 4.2±0.7** 4.5±0.4** 19.9±2.8 15.5±0.1* 20.5±0.7
U87 S 29.3 32.7 38.8 82.5 79.3 32.6 22.9 25.5
25.3 32.0 30.8 73.4 82.4 26.4 25.9 26.9
Flow cytometry was performed at the indicated intervals post FdUrd pre-treatment (1 μM FdUrd for 1 h). Mean values ±1 SD of three
independent FACS analyses are given for LN229 and U251 cells. S-phase results of two FACS analyses are given for U87 cells.
* and ** denote results that were significantly (p<0.05) or highly significantly (p<0.001) different compared with untreated control cells.
(*) and [*] indicate differences that were close to significance, at p<0.07 and p<0.15, respectively
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incubated with FdUrd alone, dThd inhibited IdUrd DNA
incorporation and the absence of primary antibody also
gave a negative result (data not shown).
As shown (Fig. 3 and Table 1), the rate of S-phase cells
increased to 69.5% or higher at 16–24 h after FdUrd pre-
treatment, compared with baseline rates of 28.7%, 18.5%
and 25.5% for un-pretreated LN229, U251 and U87 cells,
respectively. The S-phase increase at 16 and 24 h was
highly significant (p<0.001) compared with both untreated
cells and cells evaluated immediately after FdUrd pre-
treatment (t=0). G1 and G2 phases decreased at these times
to the benefit of the S phase. Interestingly, while the cell
cycle distribution of LN229 and U87 cells had returned to
about baseline 72 h after FdUrd removal (Table 1), results
in respect of U251 cells showed an under- and over-
reaction of the cell phases which, compared with baseline
results, was either significant (G2 phase) or close to being
significant (p<0.07), suggesting that these cells remained
partially synchronised.
S-phase cells were further analysed by plotting the
number of cells against DNA content (Fig. 4 shows a
representative experiment). This sub-analysis of the S-
phase fractions showed that LN229 and U87 accumulated
in early S phase up to 16 h and U251 cells up to 24 h post
FdUrd pre-treatment. Release of the early S-phase block
was observed at 24 h for LN229 and U87 and at 48 h for
U251 cells.
125I-IdUrd DNA incorporation rate in the presence of 3
μM unlabelled IdUrd
In order to directly compare radio-IdUrd DNA incorpora-
tion and cell cycling, a comparison at identical IdUrd
concentrations (3 μM unlabelled IdUrd) was performed on
LN229 and U251 cells. In the FACS analysis, the use of 3
or 10 μM unlabelled IdUrd gave identical cell cycle
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distributions with notably similar S-phase rates after FdUrd
pre-treatment (Table 1). 125I-IdUrd DNA incorporation
measurements were therefore performed using incubation
of pre-treated cells with 125I-IdUrd in the presence of 3 μM
unlabelled IdUrd. The presence of the additional 3 μM
unlabelled IdUrd partially decreased the radio-IdUrd DNA
incorporation compared with experiments with radio-
IdUrd alone. In both cell lines, however, the optimal
DNA incorporation increase was still observed at 16–24 h
post FdUrd (Fig. 5). For both cell lines, LN229 and U251,
the increase in uptake at 16 and 24 h was highly significant
(p<0.001) compared with untreated cells, and also com-
pared with the incorporation immediately after FdUrd
pre-treatment. These results therefore show that, under iden-
tical IdUrd concentrations, S-phase accumulation and the
highest DNA incorporation rate of 125I-IdUrd remained
time-correlated.
Radiosensitivity after FdUrd pre-treatment
These experiments were performed in order to test whether
the S-phase arrested cells would exhibit any radio-
resistance. LN229 and U251 cells were pre-treated or not
with 1 μM FdUrd for 1 h. Cells were then irradiated with 2
or 6 Gy immediately after FdUrd exposure or after an
interval of 20 h, and survival evaluated by colony-forming
assay. Results showed reproducibly that pre-treated cells
were equally or more radiosensitive than un-pretreated
cycling control cells (Fig. 6). An increased cytotoxic effect
(statistically significant, p<0.05) after FdUrd pre-treatment
was observed in LN229 cells at both 0 and 20 h post
irradiation with 2 and 6 Gy, while in U251 cells such a
significant difference was only observed at 20 h post FdUrd
and was limited to the 6-Gy irradiation. These results thus
show the absence of any radio-resistance of the S-phase-
enriched cell populations.
Discussion
A rational approach to radio-IdUrd Auger radiation therapy
requires targeting of the highest possible number of cells
and high DNA incorporation of radio-IdUrd. Previously,
we have shown that short-term, non-toxic concentrations of
FdUrd are able to induce high percentage DNA incorpo-
ration of radio-IdUrd in vitro and in vivo [6]. However, the
number of targeted cells, namely the cells in S phase,
remained low at the time of incubation/administration of
radio-IdUrd immediately after FdUrd.
In this study, we therefore investigated cellular cycling
and radio-IdUrd DNA incorporation after different inter-
vals post FdUrd pre-treatment in three glioblastoma cell
lines, aimed particularly at optimising S-phase targeting.
We were able to show with highly reproducible FACS
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Fig. 6. Survival fractions of LN229 (a) and U251 (b) cells after
external beam irradiation. Cells were irradiated after 0- and 20-h
intervals following pre-treatment or not with 1 μM FdUrd for 1 h:
(♦), un-pretreated controls; (☐), 0 h post FdUrd; (▲), 20 h post
FdUrd. Mean values ±1 SD of three independent experiments are
shown; each experiment was performed with triplicate measure-
ments per condition. Survival in the colony-forming assay has been
normalised with unirradiated but otherwise identically treated
control cells (S/So). Note that the increased cytotoxic effect
following FdUrd pre-treatment was statistically significant
(p<0.05) in LN229 cells at both 0 and 20 h post irradiation with 2
and 6 Gy, while in U251 cells such a significant difference was
observed only at 20 h and 6-Gy irradiation
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results that cell cycle evolution was remarkably similar in
the three different glioblastoma cell lines. Baseline S-phase
rates of untreated cells were between 18.5% and 28.7%. S-
phase cells then increased gradually up to 69.5% or more
16 and 24 h after 1 h pre-treatment with 1 μM FdUrd. This
corresponds to an increase by a factor of between 2.5 and
4.1 over the baseline S-phase rates in the three cell lines.
We also observed a similar S-phase rate accumulation after
FdUrd pre-treatment in the ovarian cancer cell line SKOV3
(data not shown). These data confirm and extend a similar
observation after FdUrd pre-treatment that was described
for the human colon carcinoma cell line HT 29 [9]. HT 29
showed a particularly short doubling time of 22–24 h, and
it was not obvious that cell lines with a longer cycling time
would show similar S-phase accumulation. Furthermore, in
the three glioblastoma cell lines explored, the difference in
p53 expression [15], as observed frequently in recurrent
tumour [20, 21], had no major impact on S-phase
accumulation post FdUrd. In fact, the accumulation peaked
to similar degrees in the three glioblastoma cell lines 16 h
post FdUrd exposure.
The results reported here indicate that the observed S-
phase increase corresponds to a synchronisation of cells
rather than just an accumulation, since a grouped release
from the block in early S phase was observed in the three
glioblastoma lines after 16–24 hours. Furthermore, U251
cells remained partially synchronised as late as 72 h after
FdUrd pre-treatment. The high S-phase rate in the three cell
lines at 16 and 24 h post FdUrd is remarkable since the
measured doubling times of these cells varied between 24
and 34 h.
Cells accumulated in S -phase as late as 16 and 24 h
after FdUrd pre-treatment continued to take up and in-
corporate IdUrd as soon as it became available. This was
shown by their ability to incorporate unlabelled IdUrd in
micromolar concentrations in the FACS analysis and also
in nanomolar concentrations in the 125I-IdUrd DNA incor-
poration assay. Indeed, the radio-IdUrd DNA incorporation
peaked at the time of maximal S-phase accumulation.
A further interesting observation was the high percent-
age of radio-IdUrd incorporated into tumour cells. In fact,
the short availability of radio-IdUrd in vivo is a significant
limitation for therapy. In these in vitro experiments, the
uptake in absolute amount of radio-IdUrd rose from
baseline incorporations of 2.4%–3.6% to between 16.4%
and 50.7% at 24 h post FdUrd pre-treatment. Again, we
observed a similar increase in uptake in SKOV3 ovarian
cancer cells (results not shown). In vivo, without taking
advantage of any S-phase increase after an interval post
FdUrd, we observed that FdUrd pre-treatment enhanced
the tumour uptake of radio-IdUrd in LN229 cells after
intratumoural injections: tumour uptake reached 19.8% of
the injected dose compared with only 4.1% in animals not
pre-treated with FdUrd [12]. These data demonstrate that
the short bio-availability of radio-IdUrd might be at least
partially circumvented by the use of FdUrd or other dThd
synthesis-blocking agents.
Evidence derived from radiobiology indicates that cell
radiosensitivity is maximal in the M, late G1 and early S
phases and minimal in the early G1 and G2 phases [22].
However, arrested cells might respond differently to
irradiation than cycling cells. It has been reported that
fluoropyrimidine-mediated radiosensitisation is dependent
on progression of cells into S phase under conditions of
altered deoxynucleotide triphosphate pools [23]. The
observation that the S-phase-enriched population 20 h
post FdUrd treatment remained as, or slightly more,
sensitive than untreated cycling cells therefore appears
favourable. However, Auger radiation therapy with 123I-
or 125I-IdUrd will be active over one or several days,
respectively. Efficacy of Auger radiation treatment, there-
fore, might be less dependent on cell cycling than external
beam photon therapy, since Auger radiation induces a high
percentage of double strand breaks that cannot be repaired
efficiently.
These data might pave the way for treatment of high
percentages of tumour cells in a single therapy cycle with
Auger radiation pharmaceuticals such as 123I- or 125I-
IdUrd. Furthermore, it has recently been shown that Auger
radiation therapy can also produce a bystander effect [24].
This might allow treatment in a single cycle of more than
just the S-phase cells targeted 16 h after the FdUrd pre-
treatment. However, the capacity to induce S-phase
synchronisation in vivo remains to be demonstrated.
In conclusion, our results confirm and extend earlier
observations in a colorectal cancer line to three human
glioblastoma cell lines, with the observation of high
percentage accumulation in early S phase delayed after
FdUrd pre-treatment. We have further shown that these S-
phase cells remained accessible to radio-IdUrd targeting at
nanomolar up to micromolar concentrations and incorpo-
rated high percentages. Thus, highest radio-IdUrd DNA
incorporation and S-phase accumulation were observed
16–24 h following FdUrd pre-treatment. The S-phase-
enriched cell population was also shown to be as, or more,
radiosensitive than un-pretreated cycling cells. The short
FdUrd pre-treatment itself was non-toxic. Viewing these
considerations in conjunction, it appears that the combina-
tion of FdUrd and radio-IdUrd could allow the rational
design of a local Auger radiation treatment of cancer at
optimised timing post FdUrd.
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